More than 330 million vaccinations have been administered in the fight against Covid-19, and a new vaccine candidate is now ready to enter the ring. Novavax recently completed its final analyses and will seek FDA and international approval in the coming weeks. The new candidate uses a mechanism to prompt immune responses that is different from vaccines already in circulation, but remains effective against non-variant forms of the virus. Here I discuss the results and implications of the Novavax trials and the vaccine’s performance against surging variants of SARS-CoV-2. The press release details a United Kingdom trial of 15,000 participants....